UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for hepatitis B and hepatitis C in the United Kingdom. Explore treatment pathways including direct-acting antivirals and functional cure research.
Hepatitis B and C affect ~270,000 and ~143,000 people respectively in the UK. Both can cause chronic liver infection leading to cirrhosis and liver cancer. Hepatitis C can now be cured in >95% of patients with direct-acting antivirals. Hepatitis B can be controlled but a functional cure (complete elimination) remains the goal of current research.
Direct-acting antivirals (DAAs) have revolutionised hepatitis C treatment: 8-12 weeks of oral tablets cures >95% of patients with minimal side effects. Regimens include sofosbuvir/velpatasvir (Epclusa), glecaprevir/pibrentasvir (Mavyret), and sofosbuvir/ledipasvir (Harvoni). NICE recommends treatment for all HCV patients regardless of liver disease stage. The NHS aims to eliminate hepatitis C by 2025.
Current treatment: pegylated interferon (finite course) or nucleos(t)ide analogues (entecavir, tenofovir) long-term. These suppress the virus but rarely achieve a functional cure (HBsAg loss). Research is focused on combination approaches to achieve functional cure: capsid inhibitors, siRNA therapies (bepirovirsen), therapeutic vaccines, and entry inhibitors. NICE recommends treatment for active HBV with elevated ALT or significant fibrosis.
Active UK hepatitis trials include: HBV functional cure combinations (siRNA + capsid inhibitor + immunotherapy), HCV elimination strategies (find-and-treat programmes for underserved populations), liver fibrosis reversal, therapeutic vaccines for HBV, and point-of-care diagnostics. The NHS England HCV elimination programme is the first of its kind globally.
We'll email you when new UK clinical trials start recruiting. Free, and you can unsubscribe anytime.
Free AI-powered matching - no signup required
